Olivier

Så længe rentesænkninger ikke kan afvises helt – uundgåeligt rally i risikoaktiver

Biotech and Life Science indexes finally moving out of the shadow, but unfortunately, not all investors nor companies are affected

Outlook for 2024 – is it pessimistic or just cautious?

Sværere og sværere at finde fundamentale grunde til styrken i aktiemarkedet

Biotech and Life Science stocks takes a pause while underlying deal activity shows no sign of stopping

New year with a rebound in the Danish SaaS sector

”Goldilocks” såret, men kan kæmpe videre

Announcement: Launch of HCA Corporate Finance

Will BioTech and Life Science stocks finally catch up as we enter 2024?

Rebound to the global SaaS sector in 2023 due to AI and declining interest rates – but not seen in the Danish SaaS sector

December fortsatte hvor november slap – men hvad så nu?

Med FED som medspiller, ingen grund til ikke at gå all in